Gerold Meinhardt

机构：Daiichi Sankyo (United States)

发表论文 93 篇 · 总被引 13959 次 · h-index 32

代表论文

• Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer (2022 · New England Journal of Medicine · 被引 2709)
• Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies (2017 · Journal of Hepatology · 被引 583)
• Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial (2018 · Journal of Hepatology · 被引 357)
• Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial (2018 · Gut · 被引 339)
• Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma (2019 · Gastroenterology · 被引 211)
• Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer (2023 · Nature Communications · 被引 173)